Phosphoric Acid Monomethyl Ester

Phosphoric Acid Monomethyl Ester

SCHEMBL4264353

CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)O)cc3)c2)c2cc(OC)c(OC)cc2n1.COP(=O)(O)O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.79
PDE4B Q07343 1/20 0.79
PDE4C Q08493 1/20 0.79
PDE4D Q08499 1/20 0.79
EGFR P00533 1/20 0.44
MAPK14 Q16539 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CTNNB1 P35222 2/20 0.43
TCF7L2 Q9NQB0 2/20 0.43
TRPV1 Q8NER1 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RXFP1 Q9HBX9 2/20 0.41
TSHR P16473 1/20 0.41
WHR1 P49842 1/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296279 0.95 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DEGFR
Hydrochloric Acid SCHEMBL296658 0.95 PDE4A (0.84) PDE4APDE4BPDE4CPDE4DEGFR
Methanesulfonic Acid Methyl Ester SCHEMBL4261958 0.90 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL3893441 0.90 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL296765 0.90 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL371380 0.89 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL297387 0.89 PDE4A (0.87) PDE4APDE4BPDE4CPDE4DEGFR
SCHEMBL1942703 0.88 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DADORA3
Lotamilast SCHEMBL29373383 0.88 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DEGFR
Lotamilast SCHEMBL369445 0.88 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530654-B2 Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-09-10 US disclosed
US-20090062539-A1 CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062539-A1 CRYSTALS, AMORPHOUS SUBSTANCES OR SALTS OF METHYL N-[3-(6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLIN-4-YL) PHENYL] TEREPHTHALAMIC ACID PDE4A, PDE4B, PDE7A PDE4A 1/4885PDE4B 2/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.